Clinical trials
Retinopathy clinical trials
Below are recruiting retinopathy clinical trials, each written for real people, not researchers. We’re tracking 114 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07520045Recruiting
Eye Injections for Diabetic Vision Loss: Two Treatment Comparison
This study compares two injectable medications (faricimab and biosimilar ranibizumab) used to treat diabetic retinopathy, a serious eye condition that can cause vision loss in people with diabetes. The trial will measure how well each medication works and track specific markers in your eye to understand treatment response.
OsijekAges 18 years+ - NCT07500324Recruiting
Searching for new markers in age-related eye diseases
This study looks for proteins in the blood and eye fluids that may help doctors better understand and monitor three common eye conditions: age-related macular degeneration, diabetic retinopathy, and retinal detachment. If you have one of these conditions, or if you are a healthy control with no retinal disease, you may be able to help by giving a small sample of blood or fluid from your eye during a routine procedure.
Roma, ItalyAges 18 years+ - NCT07468058Recruiting
Diabetic eye disease study in Da Nang
This study looks at how common diabetic retinopathy is and what factors increase the risk. It may help find better ways to prevent vision loss in people with diabetes.
Da NangAges 18 years+ - NCT07458516Recruiting
Observing eye disease progression in type 2 diabetes
This study closely follows people with type 2 diabetes who have early signs of diabetic retinopathy (damage to the retina from diabetes) to see how the condition changes over time. It does not test a new treatment but monitors the eye's health closely. It may be a good fit if you have diabetic retinopathy that does not need immediate treatment.
CoimbraAges 35–80 - NCT07296952Recruiting
Improving transportation for diabetic retinopathy patients
This study tests a new way to help people with diabetic retinopathy get to their eye appointments. It aims to make transportation easier for patients who have Medicaid insurance.
Chicago, IllinoisAges 18 years+ - NCT06879834Recruiting
AI software for diabetic eye screening
This study tests an AI platform that checks for diabetic retinopathy, a common eye problem in people with diabetes. It aims to see if the AI can spot signs of damage early, so you can get treatment sooner.
OdesaAges 18–90 - NCT06892353Recruiting
AI eye screening for diabetic retinopathy
This trial tests a new AI-powered, do-it-yourself screening system for diabetic retinopathy. It may help find early signs of eye disease in people who haven't had an eye exam in the past year.
Hong KongAges 18 years+ - NCT07259928RecruitingPhase 2
Testing ANXV for diabetic retinopathy or retinal vein occlusion
This trial tests a new drug called ANXV (Annexin A5) to see if it is safe and can help people with diabetic retinopathy or a recent retinal vein occlusion. The goal is to reduce eye damage and improve vision.
LondonAges 18 years+ - NCT06899529Recruiting
Bevacizumab after eye surgery for diabetic retinopathy
This trial tests whether giving bevacizumab (a medicine that slows abnormal blood vessel growth) right after vitrectomy (a surgery to remove blood or scar tissue from the eye) can help people with advanced diabetic eye disease. The goal is to improve vision and reduce the need for more treatments.
Querétaro City, QuerétaroAges 18 years+ - NCT07235085RecruitingPhase 3
Study of OTX-TKI implant for moderate to severe NPDR
This study tests an eye implant (OTX-TKI) that slowly releases a medicine to slow or stop worsening of non-proliferative diabetic retinopathy (NPDR) — an early form of diabetic eye disease. It's for people with moderately severe to severe NPDR who haven't had significant treatments like laser or injections in that eye.
Hagerstown, MarylandAges 18 years+ - NCT07236879Recruiting
AI eye test for diabetes patients in primary care
This trial uses an artificial intelligence (AI) system to check for diabetic eye disease (retinopathy) during your regular doctor visit. It aims to detect problems early so you can get treatment sooner.
Porto Alegre, Rio Grande do SulAges 18 years+ - NCT06787482RecruitingPhase 1/Phase 2
Peptide therapy for retinitis pigmentosa
This trial tests a new peptide therapy for people with retinitis pigmentosa (RP), a genetic eye disease that causes vision loss. The goal is to see if the treatment is safe and can help slow or improve vision loss.
CairoAges Any age - NCT06955611Recruiting
Is home monitoring safe for early diabetic eye problems?
This trial tests whether monitoring certain diabetic eye changes in the community is as safe as hospital checks. It's for people with early signs of diabetic eye disease that haven't yet reached a more advanced stage.
HaverfordwestAges 18 years+ - NCT07151001Recruiting
AI test for early diabetic eye disease (retinopathy)
This trial uses an AI system to test if it can find early signs of diabetic eye disease (diabetic retinopathy) in people with diabetes. If you have diabetes but no known eye problems, the AI might help catch issues early.
Richmond Hill, New YorkAges 22 years+ - NCT07135570Recruiting
My Eyes, My Light: Amar Chokh, Amar Alo
This trial is studying people living in Char Fasson, Bangladesh, to see who might have undiagnosed eye problems. It's a local screening program to catch eye issues early.
Char Fasson, BholaAges 35 years+ - NCT06817265RecruitingPhase 3
TNTL for diabetic eye disease (non-proliferative)
This study tests if a drug called TNTL can help people with type 2 diabetes who have early-stage diabetic eye disease (non-proliferative diabetic retinopathy) without severe vision loss. It aims to see if the treatment is safe and effective in slowing or improving the condition.
Xuancheng, AnhuiAges 18–75 - NCT06821399Recruiting
Better eye care for type 2 diabetes
This study is testing a better way to diagnose and manage eye problems (diabetic retinopathy) in people with type 2 diabetes. It aims to improve how doctors find and treat these issues to help protect your vision.
LanzhouAges 20–79 - NCT06782997Recruiting
Using a quick eye test to check for diabetes eye damage
This trial tests if a special eye exam (electroretinogram) done by a nurse can find early signs of diabetic retinopathy in people with diabetes who have no known eye problems yet. It aims to make screening easier and more accessible.
ReimsAges 18 years+ - NCT06717412Recruiting
Low-dose conbercept for retinopathy of prematurity
This trial tests whether a low dose of conbercept, given as an eye injection, can safely treat type 1 ROP (an eye disease in premature babies). The goal is to stop abnormal blood vessel growth and prevent vision loss.
Xi'an, ShaanxiAges Any age - NCT06035887Recruiting
New eye test for hydroxychloroquine damage
This trial tests a new type of eye test (ERG) to detect early damage from hydroxychloroquine, a drug used for conditions like lupus and rheumatoid arthritis. If you take hydroxychloroquine or have never taken it, you might help find better ways to protect your vision.
London, LondonAges 18 years+ - NCT06701721RecruitingPhase 1
Study of THN391 eye injection for diabetic macular edema
This trial tests an experimental eye injection called THN391 for people with diabetic macular edema, a condition that causes vision loss due to swelling in the back of the eye. The study aims to see if the treatment is safe and may help improve vision.
Parramatta, New South WalesAges 18–80 - NCT06612541Recruiting
Eye imaging test for premature babies at risk of ROP
This study tests a new eye imaging device to check for retinopathy of prematurity (ROP), a condition that can affect vision in premature babies. It may help doctors diagnose ROP earlier and more easily at the bedside.
Nashville, TennesseeAges 6 months–8 months - NCT06315556Recruiting
Study of Eylea for preterm babies with retinopathy of prematurity in the UK
This study collects information on how the medicine Eylea is given to preterm babies with retinopathy of prematurity (an eye problem in premature infants) using a special dosing device. The goal is to see how the treatment works in everyday hospital care.
Multiple LocationsAges Up to 1 year - NCT04187443RecruitingPhase 1
Drug MS-553 for diabetic eye swelling with reduced vision
This Phase 1 trial tests MS-553 to see how it works and how safely it can be given to people with diabetic retinopathy causing central macular swelling (macular edema). You may be considered if your vision and eye scan results match, and if you can follow frequent study visits.
Changsha, HunanAges 18 years+
Hear when a new Retinopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for retinopathy?
- Yes. Clin2 currently lists 114 recruiting retinopathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a retinopathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a retinopathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.